Bio-Techne (TECH) AI Stock Analysis

• Market Cap: $9.93B
• Dividend Yield: 0.48%
• Average Volume (3M): 2.48M
• Price to Earnings (P/E): 143.8
• Beta (1Y): 0.93
• Revenue Growth: 5.23%
• EPS Growth: -56.70%
• Country: US
• Employees: 3,100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.53
• Shares Outstanding: 155,693,440
• 10 Day Avg. Volume: 1,675,298
• 30 Day Avg. Volume: 2,482,807
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 6.77
• Enterprise Value/Gross Profit: 10.44
• Enterprise Value/Ebitda: 36.99
• 1Y Price Target: $67.20
• Price Target Upside: 1.73% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 72 Outperform
• Price Target: $73.00 ▲(10.51% Upside)

Bio-Techne's overall stock score reflects a stable financial position with strong cash flow and prudent leverage. The technical analysis shows bullish momentum, but the high P/E ratio suggests potential overvaluation. Strategic moves to enhance profitability are positive, but challenges in academia and biotech funding uncertainties remain risks.

Positive Factors

Strategic Partnerships

The expanded agreement with Oxford Nanopore Technologies enhances Bio-Techne's ability to develop genetic products, strengthening its market position in genetic diagnostics and potentially driving long-term revenue growth.

Operating Margin Improvement

Divesting Exosome Diagnostics allows Bio-Techne to focus on core growth areas, enhancing operational efficiency and improving operating margins by 200 basis points, which supports long-term profitability.

Strong Cash Flow

Robust operating cash flow and strong coverage ratio indicate efficient cash generation, providing Bio-Techne with financial flexibility to invest in growth opportunities and withstand economic fluctuations.

Negative Factors

Declining Profit Margins

Decreasing net profit margins suggest rising operational costs or inefficiencies, which could hinder long-term profitability unless addressed through cost management or operational improvements.

Inconsistent Revenue Growth

Inconsistent revenue growth reflects challenges in maintaining steady market expansion, potentially impacting long-term financial stability and necessitating strategic adjustments to sustain growth.

Biotech Funding Uncertainty

A constrained biotech funding environment poses risks to Bio-Techne's growth, as reduced funding may limit customer spending and impact demand for its products, affecting revenue potential.

Bio-Techne Business Overview & Revenue Model

Company Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

How the Company Makes Money

Bio-Techne generates revenue through multiple streams, primarily from the sale of reagents, instruments, and diagnostic products. The Protein Platforms segment is a significant contributor to the company's earnings, as it provides essential research tools that are in high demand within the life sciences community. Additionally, the Diagnostics segment offers products that cater to the growing field of molecular diagnostics, contributing to recurring revenue from both product sales and potential partnerships with clinical laboratories. Bio-Techne also engages in strategic collaborations with other companies and research institutions, enhancing its market presence and expanding its product offerings, which further drives revenue. The company benefits from a strong customer base, including major pharmaceutical companies, which rely on Bio-Techne's products for drug development and testing.

Bio-Techne Financial Statement Overview

Summary

Bio-Techne shows a stable financial position with strong cash flow generation and prudent leverage. However, declining profitability margins and inconsistent revenue growth pose challenges. The company needs to address operational inefficiencies to improve overall financial performance.

Income Statement

Bio-Techne's revenue growth has been inconsistent, with a significant drop in growth rate in the latest year. Gross profit margin remains strong, but net profit margin has decreased, indicating rising costs or inefficiencies. EBIT and EBITDA margins have also declined, suggesting pressure on operational profitability.

Balance Sheet

The company maintains a healthy debt-to-equity ratio, indicating prudent leverage management. However, return on equity has decreased, reflecting lower profitability. The equity ratio is stable, showing a solid capital structure.

Cash Flow

Operating cash flow remains robust, with a strong coverage ratio. Free cash flow growth is positive, though it has slowed down. The free cash flow to net income ratio is high, indicating efficient cash generation relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.22B	1.22B	1.16B	1.14B	1.11B	931.03M
Gross Profit	790.27M	790.27M	769.73M	769.82M	756.50M	632.85M
EBITDA	223.07M	216.88M	310.37M	460.56M	420.12M	258.47M
Net Income	73.40M	73.40M	168.10M	285.26M	272.05M	140.41M
Balance Sheet
Total Assets	2.56B	2.56B	2.70B	2.64B	2.29B	2.26B
Cash, Cash Equivalents and Short-Term Investments	162.19M	162.19M	152.86M	204.31M	247.03M	231.55M
Total Debt	444.06M	444.06M	419.54M	454.96M	325.97M	420.55M
Total Liabilities	639.06M	639.06M	635.02M	672.18M	593.79M	691.72M
Stockholders Equity	1.92B	1.92B	2.07B	1.97B	1.70B	1.57B
Cash Flow
Free Cash Flow	256.55M	256.55M	236.10M	216.15M	280.36M	307.86M
Operating Cash Flow	287.56M	287.56M	298.98M	254.39M	325.27M	352.16M
Investing Cash Flow	-35.18M	-35.18M	-203.03M	-265.65M	-96.85M	-243.52M
Financing Cash Flow	-253.91M	-253.91M	-122.40M	22.62M	-242.85M	-62.55M

Bio-Techne Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 66.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Positive. The current price of 66.06 is above the 20-day moving average (MA) of 60.14, above the 50-day MA of 56.17, and above the 200-day MA of 57.04, indicating a bullish trend. The MACD of 2.45 indicates Negative momentum. The RSI at 72.66 is Negative, neither overbought nor oversold. The STOCH value of 86.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TECH.

Bio-Techne Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	76 Outperform	$7.69B	15.28	179.14%	―	34.97%	71.10%
TECH	72 Outperform	$9.93B	143.83	3.68%	0.48%	5.23%	-56.70%
CORT	70 Outperform	$7.76B	64.95	21.42%	―	25.71%	4.48%
JAZZ	65 Neutral	$8.34B	―	-10.84%	―	4.52%	-205.13%
ROIV	61 Neutral	$12.20B	―	-15.84%	―	-85.32%	-111.82%
RYTM	55 Neutral	$7.25B	―	-1334.54%	―	53.55%	30.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bio-Techne Corporate Events

Bio-Techne Reports Solid Q4 2025 Results Amid Strategic Shift

Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, aiding scientific investigations and drug discovery efforts. With a diverse product portfolio, the company serves the biopharma and academic research communities worldwide.

Bio-Techne’s Earnings Call: Growth Amid Challenges

Bio-Techne’s recent earnings call painted a picture of solid organic growth and strategic positioning in core markets, particularly in biopharma and cell therapy. Despite these strengths, the company remains cautious due to uncertainties in academic funding, challenges in the biotech market, and policy-related headwinds.

Bio-Techne Divests Exosome Diagnostics to Boost Growth

Bio-Techne reported its fourth quarter fiscal 2025 results, highlighting a 3% organic revenue increase to $317.0 million and a full-year organic revenue growth of 5% to $1.2 billion. Despite a decrease in GAAP EPS to ($0.11) from $0.25 a year ago, adjusted EPS rose to $0.53 from $0.49. The company announced the divestiture of its Exosome Diagnostics business to focus on high-growth areas, which is expected to enhance profitability. The Protein Sciences segment showed strong growth, while the Diagnostics and Spatial Biology segment faced challenges due to unfavorable product mix.

The most recent analyst rating on (TECH) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Bio-Techne stock, see the TECH Stock Forecast page.